Lipid-based formulations for intestinal lymphatic delivery

被引:323
作者
O'Driscoll, CM [1 ]
机构
[1] Univ Dublin Trinity Coll, Dept Pharmaceut & Pharmaceut Technol, Dublin 2, Ireland
关键词
intestinal lymphatics; lipophilic drugs; emulsion; microemulsion; self-emulsifying drug delivery system (SEDDS); micellar systems; chylomicrons;
D O I
10.1016/S0928-0987(02)00051-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The current state of the art of intestinal lymphatic transport is given by reviewing the more recent publications, which have utilized lipid-based vehicles. The results published often show variable trends depending on, the design of the vehicle, the components used, the physicochemical properties of the drug, the animal model and experimental techniques, these variables often make direct comparisons difficult. Traditionally intestinal lymphatic delivery has been expressed as a percentage of the dose transported in the lymph. Using this parameter results obtained to date, with lipid-based vehicles, are somewhat disappointing maximising at approximately 20-30%, for highly lipophilic compounds including DDT and halofantrine (Hf). Recent data, monitoring Hf, in a fed versus fasted dog study, have shown that a higher degree of lymphatic transport is possible (>50% dose) in the postprandial state, this study should result in stimulating renewed interest in the potential of achieving significant levels of lymphatic targeting. Although some relevant features controlling lymphatic transport have been identified over the years a deeper appreciation of all the mechanisms, which is vital for therapeutic exploitation of lymphatic transport, is still unrealized. This review analyses the success and limitations of a formulation approach using lipid-based vehicles and highlights potential areas for further research. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:405 / 415
页数:11
相关论文
共 92 条
[1]  
ANDERSON LJ, 1989, J LIPID RES, V30, P1819
[2]  
[Anonymous], 1992, LYMPHAT TRANSP DRUGS
[3]   Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers [J].
Batrakova, EV ;
Li, S ;
Miller, DW ;
Kabanov, AV .
PHARMACEUTICAL RESEARCH, 1999, 16 (09) :1366-1372
[4]  
Caliph SM, 2000, J PHARM SCI, V89, P1073, DOI 10.1002/1520-6017(200008)89:8<1073::AID-JPS12>3.0.CO
[5]  
2-V
[6]   LIPID DIGESTION AND ABSORPTION [J].
CAREY, MC ;
SMALL, DM ;
BLISS, CM .
ANNUAL REVIEW OF PHYSIOLOGY, 1983, 45 :651-677
[7]  
Charman SA, 2000, J PHARM SCI, V89, P168, DOI 10.1002/(SICI)1520-6017(200002)89:2<168::AID-JPS4>3.3.CO
[8]  
2-H
[9]   Lipophilic prodrugs designed for intestinal lymphatic transport [J].
Charman, WN ;
Porter, CJH .
ADVANCED DRUG DELIVERY REVIEWS, 1996, 19 (02) :149-169
[10]   ESTIMATING THE MAXIMAL POTENTIAL FOR INTESTINAL LYMPHATIC TRANSPORT OF LIPOPHILIC DRUG MOLECULES [J].
CHARMAN, WNA ;
STELLA, VJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 34 (1-2) :175-178